Amphia is een ziekenhuis met vestigingen in Breda, Oosterhout en Etten-Leur. Op de hoofdlocatie Molengracht is in 2019 een nieuw gebouw in gebruik genomen, als uitbreiding op het reeds bestaande ziekenhuis. Op 11 juni 2021 verhuisde de laatste polikliniek Oogheelkunde van locatie Langendijk naar locatie Molengracht.

During the past decade, Amphia Ziekenhuis conducted 166 clinical trials. In the 10-year time frame, 166 clinical trials started and 42 clinical trials were completed, i.e. on average, 25.3% percent of trials that started reached the finish line to date. In the past 5 years, 70 clinical trials started and 26 clinical trials were completed. i.e. 37.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Amphia Ziekenhuis" #1 sponsor was "UMC Utrecht" with 15 trials, followed by "Hoffmann-La Roche" with 13 trials sponsored, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 12 trials sponsored, "Maastricht University Medical Center" with 11 trials sponsored and "Boehringer Ingelheim" with 11 trials sponsored. Other sponsors include 195 different institutions and companies that sponsored additional 105 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Amphia Ziekenhuis" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 21 trials as a collaborator, "Erasmus Medical Center" with 15 trials as a collaborator, "Amphia Hospital" with 13 trials as a collaborator, "Dutch Cancer Society" with 11 trials as a collaborator and "Borstkanker Onderzoek Groep" with 8 trials as a collaborator. Other collaborators include 380 different institutions and companies that were collaborators in the rest 284 trials.

According to Clinical.Site data, the most researched conditions in "Amphia Ziekenhuis" are "Coronary Artery Disease" (19 trials), "Breast Cancer" (9 trials), "Heart Failure" (8 trials), "Atrial Fibrillation" (6 trials) and "Colorectal Cancer" (5 trials). Many other conditions were trialed in "Amphia Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Amphia Ziekenhuis" are "Drug" (129 trials), "Device" (43 trials), "Other" (41 trials), "Procedure" (38 trials) and "Diagnostic Test" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (31 trials), "Atezolizumab" (5 trials), "Bevacizumab" (5 trials), "Ocrelizumab" (4 trials) and "Pembrolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Amphia Ziekenhuis" are 232 trials for "All" genders, 23 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 101 active trials in "Amphia Ziekenhuis". 2 are not yet recruiting, 58 are recruiting, 38 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 108 completed trials in Amphia Ziekenhuis, 1 suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Amphia Ziekenhuis, 0 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 79 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 26 trials, and there were also 70 trials that are defined as “Not Applicable".